First Clinical Results of Using Embryonic Stem Cells to Treat Eye Disease Published in The Lancet
January 26, 2012
Two significant events were reported by Advanced Cell Technology concerning their use of stem cells to treat eye diseases.
First, the company said that a peer-reviewed publication of clinical results from its first patients treated at UCLA Jules Stein Eye Institute had been published online by the UK’s The Lancet. The study reported on the four-month results of a safety study initiated in human patients last July. In that study, one eye of a patient with Stargardt’s macular dystrophy (SMD), and another with the dry form of AMD were given doses of human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. After four months, no safety problems had been observed and vision improvements were noted in both patients.
The second event was the announcement that the first patient had been treated with stem cells in the UK arm of the Stargardt’s study, at Moorfields Eye Hospital on January 20th.
For the whole story, please follow this link.
You might also enjoy...
- Progress Made in Treating Stargardt’s and Dry AMD Using Embryonic Stem Cells
- Advanced Cell Technology, OHSU Researchers Show Safety, Efficacy of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelium (RPE)
- Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
- ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
- First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment
Jump down to form below to submit your own comments